Effect of cytochrome P450 2C8*3 on the population pharmacokinetics of pioglitazone in healthy caucasian volunteers

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 2, 2013, Pages 245-251

  Kadam, Rajendra ^a   Bourne, David ^b   Kompella, Uday ^a   Aquilante, Christina ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Cytochrome P450 2C8; Modeling; NONMEM; Pharmacogenetic; Pioglitazone; Population pharmacokinetic

Indexed keywords

CYTOCHROME P450 2C8; PIOGLITAZONE;

ADULT; ARTICLE; CAUCASIAN; COMPARTMENT MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MONOTHERAPY; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ARYL HYDROCARBON HYDROXYLASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84874090211     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00657     Document Type: Article

References (20)

1. Inzucchi SE, Bergenstal RM, Buse J.B., Diamant M., Ferrannini E, Nauck M, Peters A.L., Tsapas A., Wender R, Matthews DR American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364-1379 (2012).
2. DeFronzo RA, Tripathy D, Schwenke D.C., Banerji M., Bray GA, Buchanan TA, Clement SC, Henry R.R., Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner R.E., Williams K., Stentz FB, Musi N, Reaven PD, ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med., 364, 1104-1115 (2011).
3. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes, 108, S234-S242 (2000).
4. Muschler E, Lal J, Jetter A., Rattay A, Zanger U, Zadoyan G., Fuhr U, Kirchheiner J. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin. Pharmacol. Toxi col., 105, 374-379 (2009).
5. Jaakkola T, Laitila J, Neuvonen P.J., Backman JT Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin. Pharmacol. Toxicol., 99, 44-51 (2006).
6. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther., 77, 404-414 (2005).
7. Actos (pioglitazone) prescribing information. Takeda Pharmaceuticals America, Inc., Deerfield, IL, January 2012.
8. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics, 8, 917-931 (2007).
9. *3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos., 36, 73-80 (2008).
10. *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br. J. Clin. Pharmacol., 75, 217-226 (2012).
11. US-FDA. Guidance for Industry: Population Pharmacokinetics. Center for Drug Evaluation and Research, U.S. Department of health and human Services Food and Drug Administration (1999).
12. Lehr T, Schaefer HG, Staab A. Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenet. Genomics, 20, 442-450 (2010).
13. Aquilante CL, Bushman LR, Knutsen S.D., Burt LE, Rome LC, Kosmiski LA Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics, 3, 7-16 (2008).
14. . Accessed October 13, 2012.
15. Jaakkola T, Backman JT, Neuvonen M, Laitila J., Neuvonen PJ Effect of rifampicin on the pharmacokinetics of pioglitazone. Br. J. Clin. Pharmacol., 61, 70-78 (2006).
16. Sherwin CM, Ding L, Kaplan J., Spigarelli MG, Vinks AA Optimal study design for pioglitazone in septic pediatric patients. J. Pharmacokinet. Pharmacodyn., 38, 433-447 (2011).
17. Christensen ML, Meibohm B, Capparelli E.V., Velasquez-Mieyer P, Burghen GA, Tamborlane WV Single-and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J. Clin. Pharmacol., 45, 1137-1144 (2005).
18. Kaspera R, Naraharisetti SB, Evangelista E.A., Marciante KD, Psaty BM, Totah RA Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem. Pharmacol., 82, 681-691 (2011).
19. Daily EB, Aquilante CL Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics, 10, 1489-1510 (2009).
20. Karim A, Slater M, Bradford D., Schwartz L, Zhao Z, Cao C., Laurent A. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug. J. Clin. Pharmacol., 47, 37-47 (2007).